Prostate cancer, Secondary cancers
Open
Phase 1/2
This trial is looking at a drug called pembrolizumab in combination with other drugs in prostate cancer.
It is for people with metastatic castration resistant prostate cancer (mCRPC). This means that the cancer:
has spread to other parts of the body (advanced prostate cancer)
got worse despite having hormone treatment
Recruitment start: 1 February 2017
Recruitment end: 22 October 2027
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Johann DeBono
Merck Sharp & Dohme LLC
Last reviewed: 15 Jun 2025
CRUK internal database number: 17603